DALLAS and FORT WORTH, Texas, June 14, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical
company focused on developing and commercializing innovative extended-release (XR) products for the treatment of
attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, PhD, President and CEO, will present at the JMP
Securities Life Sciences Conference on Tuesday, June 21, 2016 at 1:30 p.m. ET in New York. Dr. Garg will provide a corporate
update and discuss the Company’s key milestones and events, including the launch of Adzenys XR-ODT™, the first and only
extended-release, orally disintegrating tablet for the treatment of ADHD and the Company’s first branded product commercially
available in the United States.
A live webcast of the presentation will be available on the investor section of the company’s website, http://investors.neostx.com/. The webcast will be archived on the website following the
presentation.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its
proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODT™ is the first and only commercially available
amphetamine extended-release orally disintegrating tablet for the treatment of ADHD. Neos has two other branded product candidates
in development, an XR-ODT of methylphenidate and a liquid suspension of amphetamine for the treatment of ADHD. In addition, Neos
manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of
hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS: Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics (972) 408‐1389 reisenstadt@neostx.com David Carey, Investor Relations Lazar Partners (212) 867‐1768 dcarey@lazarpartners.com
